Bradley Pharmaceuticals says sales up 36% to $102.4 million for first nine months of 2005

By Lisa Kerner

Erie, Pa., March 3 - Bradley Pharmaceuticals, Inc.'s net sales for the nine months ended Sept. 30 reached $102.4 million, an increase of $27.0 million, or 36%, over net sales for the same period in 2004, according to a company news release.

Bradley reported net income for the nine months ended Sept. 30 of $9.0 million, a decrease of $4.9 million, or 35%, from net sales for the nine months ended Sept. 30, 2004.

Earnings per diluted share for the nine months ended Sept. 30 decreased to $0.53 from $0.79 for the same period of 2004.

Bradley also reported sales of its acquired companies for the nine months ended Sept. 30: Doak Dermatologics had net sales of roughly $37.9 million, Bioglan Pharmaceuticals reported net sales of $46.9 million and Kenwood Therapeutics' net sales were about $17.6 million.

The company's annual report on Form 10-K for the year ended Dec. 31, containing its 2005 audited financial statements, is anticipated to be filed with the Securities and Exchange Commission by the end of April.

Bradley, located in Fairfield, N.J., is a specialty pharmaceutical company that acquires non-strategic brands and markets them to niche physician specialties.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.